TRENDING :  Market Movers  |  Top 50   AAPL (0%)    TSLA (0%)    TVIX (0%)    RIOT (0%)    QURE (0%)    QQQ (0%)    QCOM (0%)    PSTG (0%)    PEI (0%)    PAH (0%)    MCD (0%)    KO (0%)    JPM (0%)    IVC (0%)    IMDZ (0%)    GS (0%)    GOOGL (0%)    FDX (0%)    FCEL (0%)    FB (0%)    EA (0%)    CRM (0%)    CBS (0%)    BILI (0%)    BIDU (0%)

 ACOR - Acorda Therapeutics

$13.38 [0][0%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $10.00
Low $10.00
Average $10.00
Current $13.38

CompanyAnalyst NamePT ActionActionRatingTargetDate
Goldman SachsSalveen RichterLowersDowngradesSell$10.0012/11/18
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.


No traders tracking are currently recommending this stock


Acorda Therapeutics Becomes Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on

Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates

Acorda Therapeutics Inc ACOR announced fourth quarter 2018 earnings per share of 45 cents significantly beating the Zacks Consensus Estimate of a loss of 60 cents However the figure declined from the year ago earnings of 61 cents Acorda generated total revenues of 69 1 million in

Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Acorda Therapeutics NASDAQ ACOR Q4 2018 Earnings Conference Call Feb 14 2019 4 30 p m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator

Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates

Acorda Therapeutics ACOR came out with quarterly earnings of 0 45 per share beating the Zacks Consensus Estimate of a loss of 0 60 per share This compares to earnings of 0 61 per share a year ago These figures are adjusted for non recurring items This quarterly report represents

Array BioPharma (ARRY) Soars: Stock Adds 11% in Session

Array BioPharma Inc ARRY was a big mover last session as the company saw its shares rise nearly 11 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above

Is Acorda Therapeutics (ACOR) Stock Outpacing Its Medical Peers This Year?

The Medical group has plenty of great stocks but investors should always be looking for companies that are outperforming their peers Acorda Therapeutics ACOR is a stock that can certainly grab the attention of many investors but do its recent returns compare favorably to the sector as a

Vertex Terminates COO Ian Smith on Code of Conduct Violation

Vertex Pharmaceuticals VRTX announced the termination of Ian Smith from the post of chief operating officer COO and interim chief financial officer CFO with immediate effect Smith served the company in several leading positions for more than 17 years The company stated that